Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Benzinga Newsdesk www.benzinga.com Negative 80.5%

Neg 80.5% Neu 0% Pos 0%

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.